Flavonoids as inhibitors of human CD38

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 13, 2011, Pages 3939-3942

  Kellenberger, Esther ^a   Kuhn, Isabelle ^b   Schuber, Francis ^b   Muller Steffner, Hélène ^b  

^a Institut du Médicament de Strasbourg   (France)

^b Faculté de Pharmacie   (France)

Author keywords

Anthocyanidins; CD38; Docking; Flavonoids; Inhibition

Indexed keywords

CATECHIN; CD38 ANTIGEN; CYANIDIN 3 GLUCOSIDE; DELPHINIDIN; DIOSMETINIDIN; FISETINIDIN; FLAVONOID; LUTEOLIN; LUTEOLINIDIN; MALVIDIN CHLORIDE; MYRICETIN; PELARGONIDIN; PEONIDIN; PETUNIDIN CHLORIDE; PICEATANNOL; QUERCETAGETINIDIN; QUERCETIN; RESVERATROL; ROBINETIN; TAXIFOLIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; IC 50; MOLECULAR DOCKING; MOLECULAR INTERACTION;

ANTHOCYANINS; ANTIGENS, CD38; CATALYTIC DOMAIN; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

MAMMALIA;

EID: 79958697705     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.05.022     Document Type: Article

References (25)

1. Deaglio, S.; Aydin, S.; Vaisitti, T.; Bergui, L.; Malavasi, F. Trends Mol. Med. 2008, 14, 210.
2. Malavasi, F.; Deaglio, S.; Funaro, A.; Ferrero, E.; Horenstein, A. L.; Ortolan, E.; Vaisitti, T.; Aydin, S. Physiol. Rev. 2008, 88, 841.
3. Matrai, Z. Hematology 2005, 10, 39.
4. Chan, C. S.; Wormsley, S. B.; Pierce, L. E.; Peter, J. B.; Schechter, G. P. Am. J. Hematol. 1990, 33, 101.
5. Hoffmann, C.; Tiemann, M.; Schrader, C.; Janssen, D.; Wolf, E.; Vierbuchen, M.; Parwaresch, R.; Ernestus, K.; Plettenberg, A.; Stoehr, A.; Fatkenheuer, G.; Wyen, C.; Oette, M.; Horst, H. A. Blood 2005, 106, 1762.
6. Garnier, J. L.; Stevenson, G.; Blanc-Brunat, N.; Touraine, J. L.; Milpied, N.; Leblond, V.; Blay, J. Y. Recent Results Cancer Res. 2002, 159, 113.
7. Stevenson, G. T. Mol. Med. 2006, 12, 345.
8. Antonelli, A.; Ferrannini, E. J. Endocrinol. Invest. 2004, 27, 695.
9. Mallone, R.; Perin, P. C. Diabetes Metab. Res. Rev. 2006, 22, 284.
10. Chini, E. N. Curr. Pharm. Des. 2009, 15, 57.
11. Berger, F.; Ramirez-Hernandez, M. H.; Ziegler, M. Trends Biochem. Sci. 2004, 29, 111.
12. Grahnert, A.; Grahnert, A.; Klein, C.; Schilling, E.; Wehrhahn, J.; Hauschildt, S. Innate Immun. 2011, 17, 212.
13. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H.; de Bono, J. S. N. Eng. J. Med. 2009, 361, 123.
14. Blum, C. A.; Ellis, J. L.; Loh, C.; Ng, P. Y.; Perni, R. B.; Stein, R. L. J. Med. Chem. 2011, 54, 417.
15. Partida-Sanchez, S.; Gasser, A.; Fliegert, R.; Siebrands, C. C.; Dammermann, W.; Shi, G.; Mousseau, B. J.; Sumoza-Toledo, A.; Bhagat, H.; Walseth, T. F.; Guse, A. H.; Lund, F. E. J. Immunol. 2007, 179, 7827.
16. Kuhn, I.; Kellenberger, E.; Said-Hassane, F.; Villa, P.; Rognan, D.; Lobstein, A.; Haiech, J.; Hibert, M.; Schuber, F.; Muller-Steffner, H. Bioorg. Med. Chem. 2010, 18, 7900.
17. Muller, H. M.; Muller, C. D.; Schuber, F. Biochem. J. 1983, 212, 459.
18. Goodrich, S. P.; Muller-Steffner, H.; Osman, A.; Moutin, M. J.; Kusser, K.; Roberts, A.; Woodland, D. L.; Randall, T. D.; Kellenberger, E.; LoVerde, P. T.; Schuber, F.; Lund, F. E. Biochemistry 2005, 44, 11082.
19. Elhabiri, M.; Figueiredo, P.; Saito, N.; Brouillard, R. J. Chem. Soc., Perkin Trans. 2 1997, 355.
20. Pina, F. J. Chem. Soc., Faraday Trans. 1998, 94, 2109.
21. Wei, M.; Wynn, R.; Hollis, G.; Liao, B.; Margulis, A.; Reid, B. G.; Klabe, R.; Liu, P. C.; Becker-Pasha, M.; Rupar, M.; Burn, T. C.; McCall, D. E.; Li, Y. J. Biomol. Screening 2007, 12, 220.
22. Liu, Q.; Kriksunov, I. A.; Graeff, R.; Munshi, C.; Lee, H. C.; Hao, Q. Structure 2005, 13, 1331.
23. The three-dimensional structure of luteolinidin was sketched and energy minimized using Sybyl-X1.2 (Tripos Inc.), and then docked into the CD38 active site using Gold v5.0 (CCDC, Cambridge, UK) with the automatic settings of the genetic algorithm and the Goldscore fitness function. The coordinates of CD38 protein were prepared from the 3dzg PDB entry. All amino acid residues of chain A and the water molecule bridging Leu145 and Leu123 backbone atoms were extracted from the file and protonated using Sybyl-X1.2. The binding site was defined using a 10 Å radius sphere centered on the water molecule. The water molecule was considered as freely spinning and displaceable during the docking of luteolinidin. The docking outputs a homogeneous set of four poses (the RMSD deviation measured from the coordinates of the best pose is smaller than 1.6 Å), with good fitness values (from 63.1 to 66.87, including a minimal contribution of 17.3 for the hydrogen bonding component).
24. Munshi, C.; Aarhus, R.; Graeff, R.; Walseth, T. F.; Levitt, D.; Lee, H. C. J. Biol. Chem. 2000, 275, 21566.
25. Ji, H. F.; Li, X. J.; Zhang, H. Y. EMBO Rep. 2009, 10, 194.